A systematic review of dysgeusia induced by cancer therapies
The purpose was to review relevant scientific papers written since 1989 which focused on the prevalence and management of dysgeusia as an oral side effect of cancer treatment.
Our literature search was limited to English language papers published between 1990 and 2008. A total of 30 papers were reviewed; the results of 26 of these papers were included in the present systematic review. A structured assessment form was used by two reviewers for each paper. Studies were weighted as to the quality of the study design, and treatment recommendations were based on the relative strength of each paper.
A wide range in reported prevalence of dysgeusia was identified with the weighted prevalence from 56–76%, depending on the type of cancer treatment. Attempts to prevent dysgeusia through the prophylactic use of zinc sulfate or amifostine have been of limited benefit. Nutritional counseling may be helpful to some patients in minimizing the symptoms of dysgeusia.
Dysgeusia is a common oral side effect of cancer therapy (radiotherapy, chemotherapy, or combined modality therapy) and often impacts negatively on quality of life. From the current literature, there does not appear to be a predictable way of preventing or treating dysgeusia.
KeywordsDysgeusia Cancer therapy Amifostine
Conflict of interest statement
- 2.Amossan C et al (2003) Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the SMART (simultaneous modulated accelerated radiation therapy) boost technique. Int J Oncol Biol Phys 56(1):136–144Google Scholar
- 6.Denis et al (2003) Late toxicity results of the gortec 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55(1):93–98CrossRefPubMedGoogle Scholar
- 11.Hainsworth J et al (2002) Induction paclitaxel, carboplatin and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally-advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8:311–321CrossRefPubMedGoogle Scholar
- 23.Macquart-Moulin et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18(4):754–764PubMedGoogle Scholar
- 25.Martin M et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granuloctye-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205–1212CrossRefPubMedGoogle Scholar
- 32.Vosmik M et al (2006) IMRT with the use of simultaneous integrated boost in treatment of head and neck cancer: acute toxicity evaluation. Acta Med 49(3):167–173Google Scholar
- 36.Brennan MT, Elting LS, Spijkervet FKL. Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Support Care Cancer doi:10.1007/s00520-010-0856-3